Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine
Authors:
- 14 December 2024
- book chapter
- Published by Springer Nature
- Vol. 2893, 257-272
Abstract
One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.Keywords
This publication has 19 references indexed in Scilit:
- Culture of Adherent Cancer Cell Lines2022
- Inter-laboratory variability of A549 epithelial cells grown under submerged and air-liquid interface conditionsToxicology in Vitro, 2021
- Alternative to FBS in animal cell culture - An overview and future perspectiveHeliyon, 2021
- The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development effortsAntiviral Research, 2018
- Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector2017
- Mammalian Cell Tissue Culture TechniquesCurrent Protocols in Molecular Biology, 2017
- Monitoring Cell Growth, Viability, and Apoptosis2013
- A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®Vaccine, 2010
- Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersVaccine, 2008
- Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Propagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell LineVirology, 1997